Mehrdad Asghari Estiar1, Ali-Akbar Zare2, Rezvan Esmaeili3, Leila Farahmand3, Hassan Fazilaty4, Davood Jafari5, Tannaz Samadi3, Keivan Majidzadeh-A3. 1. Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2. Recombinant Proteins Department, Breast Cancer Research Center, ACECR, Tehran, Iran. 3. Cancer Genetics Department, Breast Cancer Research Center, ACECR, Tehran, Iran. 4. Developmental Neurobiology, Instituto de Neurociencias UMH-SIC, Alicante, Spain. 5. Department of Immunology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abstract
AIM: The expression level of NDRG3 gene is investigated among breast cancer (BC) patients. METHODS: Real-time quantitative PCR was performed. RESULTS: NDRG3 was downregulated in BC patients particularly in advanced stage of the disease. HER2 status was significantly correlated with the expression of NDRG3. Also, triple-negative BC patients showed low levels of NDRG3 expression in comparison to other subtypes. Lastly, the expression of NDRG3 had significant impact on survival, with NDRG3 downregulated patients having the worst event-free survival rate among others. CONCLUSION: We have presented that NDRG3 might be a tumor suppressor candidate. NDRG3 downregulation might be involved in the tumorigenesis and development of invasive BC in an advanced phase of the disease.
AIM: The expression level of NDRG3 gene is investigated among breast cancer (BC) patients. METHODS: Real-time quantitative PCR was performed. RESULTS:NDRG3 was downregulated in BC patients particularly in advanced stage of the disease. HER2 status was significantly correlated with the expression of NDRG3. Also, triple-negative BC patients showed low levels of NDRG3 expression in comparison to other subtypes. Lastly, the expression of NDRG3 had significant impact on survival, with NDRG3 downregulated patients having the worst event-free survival rate among others. CONCLUSION: We have presented that NDRG3 might be a tumor suppressor candidate. NDRG3 downregulation might be involved in the tumorigenesis and development of invasive BC in an advanced phase of the disease.